Your browser doesn't support javascript.
loading
Efficacy and safety of 4 kinds of hemocoagulases combined with proton pump inhibitor for nonvariceal upper gastrointestinal bleeding:a network meta-analysis / 中国药房
China Pharmacy ; (12): 600-606, 2023.
Article in Chinese | WPRIM | ID: wpr-964773
ABSTRACT
OBJECTIVE To systematically evaluate the difference of efficacy and safety of four kinds of commonly used haemocoagulases combined with proton pump inhibitor (PPI) for nonvariceal upper gastrointestinal bleeding (NVUGIB), and to provide evidence-based basis for clinical decision-making. METHODS Retrieved from PubMed, Web of Science, Wanfang data, VIP and CNKI databases, randomized controlled trials (RCTs) or cohort studies about Hemocoagulase agkistrodon blomhoffii, Haemocoagulase agkistrodonhemocoagulase and Hemocoagulase bothrops atrox combined with PPI were collected during the inception to Dec. 2021. Two researchers independently screened the literature, extracted data and evaluated the quality of included studies. ADDIS 1.16.8 software was used to conduct a Bayesian network meta-analysis. RESULTS A total of 33 studies were included, involving 3 602 patients. Results of network meta-analysis showed that: in terms of hemostatic efficacy, compared with PPI monotherapy, four kinds of haemocoagulases combined with PPI could significantly improve the hemostatic efficacy of patients (P<0.05); there was no statistical significance in the pairwise comparison of different hemocoagulases (P>0.05). The optimal probabilistic ranking of network meta-analysis was as follows: Hemocoagulase agkistrodon blomhoffii combined with PPI> Hemocoagulase bothrops atrox combined with PPI>Haemocoagulase agkistrodon combined with PPI>hemocoagulase combined with PPI>PPI alone. In terms of the incidence of adverse drug reactions (ADR), compared with PPI monotherapy, there was no statistical difference in the incidence of ADR among four kinds of haemocoagulases combined with PPI (P>0.05). There was no statistical significance in the pairwise 88325750。E-mail:fengyufei@126.com comparison of different hemocoagulases (P>0.05). The optimal probabilistic ranking of network meta-analysis was as follows: hemocoagulase combined with PPI>Hemocoagulase bothrops atrox combined with PPI>Hemocoagulase agkistrodon blomhoffii combined with PPI>Haemocoagulase agkistrodon combined with PPI>PPI alone. CONCLUSIONS Compared with PPI monotherapy, four different sources of hemocoagulases combined with PPI have better efficacy and similar safety in the treatment of NVUGIB. There is no significant difference in efficacy and safety among different hemocoagulases.

Full text: Available Index: WPRIM (Western Pacific) Type of study: Systematic reviews Language: Chinese Journal: China Pharmacy Year: 2023 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Type of study: Systematic reviews Language: Chinese Journal: China Pharmacy Year: 2023 Type: Article